Relevant events

GRIFOLS, S.A. guarantees that the texts published in this page correspond exactly and entirely with the texts sent to the CNMV by the Company or by third parties. All the significant facts, as well as any other communications, are available in the Web page of the CNMV.

2018
2017

2017

05 Dec, 2017 Grifols and the European Investment Bank sign an Euros 85 million long-term loan to support its R+D+i initiatives

22 Nov, 2017 Grifols inaugurates a new plant of the Diagnostic Division in Brazil to manufacture storage and collection bags for blood components

17 Nov, 2017 FDA approval of genetic test for alpha-1 deficiency and EMA approval of fibrin sealant

16 Nov, 2017 Payment details of the interim dividend on account of 2017 earnings

06 Nov, 2017 FDA approves a new Grifols product, fibrin sealant ("Fibrin Sealant")

30 Oct, 2017 The Board of Directors approves an interim dividend on account of 2017 results

22 Sep, 2017 FDA approves Grifols Prolastin®-C Liquid for the treatment of alpha-1 antitrypsin deficiency

25 Jul, 2017 Grifols announces the acquisition of an additional 40% equity stake in Kiro Grifols

05 Jul, 2017 Grifols acquires a 44% shareholding in GigaGen

07 Jun, 2017 Manufacturing and supply agreement

26 May, 2017 Information on the resolutions approved at the Annual General Meeting of Shareholders on May 26, 2017

02 May, 2017 Listing on the ISE of the Senior Unsecured Notes due 2025 and delisting of the Notes due 2022

21 Apr, 2017 Notice of Annual General Shareholders' Meeting 2017

18 Apr, 2017 Grifols has closed EUR 1.0 billion senior unsecured bond issue concluding its debt refinance process

06 Apr, 2017 Communication to the Irish Stock Exchange

20 Mar, 2017 Communication to the Irish Stock Exchange

06 Feb, 2017 Grifols has concluded the refinancing process of part of its financial debt

31 Jan, 2017 Grifols closes the acquisition of Hologic's share of NAT donor screening unit

12 Jan, 2017 Grifols to acquire the 49% in Access Biologicals

10 Jan, 2017 Grifols starts the refinancing process

2016
2015
2014
2013

2013

17 Dec, 2013 Information on the resolutions approved at the Extraordinary General Shareholders Meeting on December 17, 2013

20 Nov, 2013 Grifols communicates the acquisition of 21.30% of the biotechnological company TiGenix N.V.

15 Nov, 2013 Notice of Extraordinary General Shareholders' Meeting December 2013

11 Nov, 2013 Grifols to acquire Novartis diagnostics business unit for US$1,675 million

18 Sep, 2013 Grifols, S.A. informs the start of a clinical trial in phase I of the ABvac40 vaccine for patients with Alzheimer's disease

28 Aug, 2013 Grifols informs of the closing of the subscription of the shares of Aradigm Corp

15 Jul, 2013 Grifols informs that Moody's Investors Services has upgraded the company credit ratings

24 May, 2013 Information on the resolutions approved at the Annual General Shareholders Meeting on May 24, 2013

21 May, 2013 Grifols signs an exclusive worldwide license agreement with Aradigm to develop and commercialize Pulmaquin™

22 Apr, 2013 Notice of Annual General Shareholders' Meeting 2013

19 Apr, 2013 New non-voting class B shares admitted to listing

16 Apr, 2013 Registration with the Commercial Registry of the share capital increase and the issuance of new Class B non-voting shares

12 Mar, 2013 Grifols purchases ADRs from Cerberus'

04 Mar, 2013 Grifols announces the acquisition of 60% of the share capital of Progenika Biopharma S.A.

11 Jan, 2013 New non-voting class B shares admitted to listing

04 Jan, 2013 Registration with the Commercial Registry of the share capital increase and the issuance of the new Class B non-voting shares

Previous

2011

29 Dec, 2011 New non-voting class B shares admitted to listing in Spain Download (70,95 Kb)

22 Dec, 2011 Registration with the Commercial Registry of the share capital increase and the issuance of the new Class B non-voting shares

05 Dec, 2011 Announcement of Grifols S.A Share Capital Increase

02 Dec, 2011 Information on the resolutions approved at the Extraordinary General Shareholders Meeting on December 2, 2011

08 Nov, 2011 3Q results reporting date postponed

28 Oct, 2011 Notice of Extraordinary General Shareholders' Meeting December 2011

02 Aug, 2011 Grifols announces the closing of the transaction to acquire 100% of the capital of the Australian-Swiss group, Lateral-Medion

03 Jun, 2011 Execution of the agreement with Kedrion

02 Jun, 2011 Closing of the acquisition of Talecris Biotherapeutics

01 Jun, 2011 Grifols and Talecris announce that the FTC accepted for public comment the Consent Agreement

01 Jun, 2011 Changes in the board of directors

01 Jun, 2011 Registration of the "Nota sobre Acciones" (Securities Note) of the Class B non voting shares with the "CNMV" (National Securities Market Commission)

24 May, 2011 Information on the resolutions approved at the Ordinary general shareholders meeting

02 May, 2011 Grifols and Talecris Biotherapeutics announce the signing of a Consent Agreement with FTC Staff

19 Apr, 2011 Notice of Annual General Shareholders Meeting 2011

04 Mar, 2011 Grifols and Talecris disclose the extension of the outside date under their merger agreement and the financing commitments

11 Feb, 2011 New timing agreement with the FTC to provide advance notice of the consummation of the acquisition of Talecris

04 Feb, 2011 Agreement with the FTC to extend the timing of the resolution for the acquisition of Talecris

25 Jan, 2011 Information of the resolutions passed at the Extraordinary General Shareholders Meeting held January 25th 2011

17 Jan, 2011 Filing with the Securities Exchange Commission of the F-4 relating to the proposed acquisition of Talecris

13 Jan, 2011 Grifols closes USD 1.1 billion bond issue (This release will not be distributed in the United States of America, Canada, Australia or Japan)

2010

20 Dec, 2010 Notice of Extraordinary General Meeting

15 Dec, 2010 Grifols obtains EMA license to market its IVIG, Flebogamma® DIF, at 10% concentration

24 Nov, 2010 Grifols signs term loan agreements related to Talecris acquisition for USD 3.4 billion

11 Nov, 2010 Changes in the merger consideration of the Agreement and Plan of Merger as a consequence of the settlement of a class action

04 Nov, 2010 Resolution by the " Commisión Nacional de la Competencia"

02 Nov, 2010 Clarification on press releases published in certain media

30 Sep, 2010 Shareholders' commitment to the proposed acquisition of Talecris

15 Sep, 2010 Grifols expects to close for an amount of USD1.5B the first tranche of the syndicated Financing to acquire Talecris

02 Sep, 2010 Grifols obtains FDA license in the US market for its IVIG Flebogamma® DIF 10% concentration

10 Aug, 2010 Preliminary version of the F4 filed with the SEC in connection with the proposed acquisition of Talecris

20 Jul, 2010 Grifols obtains its first crédit rating from Standard & Poor's and Moody's

23 Jun, 2010 Final dividend 2009

21 Jul, 2010 Information on the resolutions passed at the Annual General Shareholders Meeting on June 21st

10 Jun, 2010 Voting agreement - amendment

10 Jun, 2010 Agreement and Plan of Merger among Grifols and Talecris Biotherapeutics Holdings Corp

07 Jun, 2010 Acquisition Announcement of Talecris Biotherapeutics Holdings Corp

07 Jun, 2010 Voting agreement

07 Jun, 2010 Analyst and investors' presentation regarding acquisition of Talecris Biotherapeutics Holdings Corp

07 Jun, 2010 Conference call details

18 May, 2010 Notice of Annual General Meeting

12 Jan, 2010 Resignation of Christian Purlow from the Board of Directors

2007

21 Dec, 2007 Appointment of Edgar D. Jannotta as member of the Appointments and Remuneration Committee (Spanish Version)

29 Oct, 2007 Grifols to announce Capital Investment Plan for 400 million euro over the next five years

27 Apr, 2007 EMEA authorization to distribute Flebogamma DIF® in Europe (Spanish Version)

10 Aug, 2007 Announcement of transfer of shares (Spanish Version)

26 Jun, 2007 Announcement on Grifols dividend payment (Spanish Version)

21 Jun, 2007 Information on the resolutions passed by the General Shareholders Meeting held on June 20th, 2007 (Spanish Version)

14 May, 2007 Annual General Meeting Announcement (Spanish Version)

04 May, 2007 Grifols enters into an agreement for the management of four new plasma centers in the USA (Spanish Version)

18 Apr, 2007 Grifols has entered into an agreement for the acquisition of Diesse. The closing of the transaction is subject to the outcome of the due diligence review, which the company expects will last until next June. (Spanish Version)

11 Apr, 2007 Morgan Stanley & Co. International Ltd announces the completion of the placement (Spanish Version)

10 Apr, 2007 Morgan Stanley & Co. International Ltd announces a private placement of 1.41% of Grifols S.A. share capital (accelerated bookbuilding) (Spanish Version)

02 Feb, 2007 Extension of the Communication number 22.629 on the FDA approval for the indication of von Willebrand disease. (Spanish Version)

01 Feb, 2007 The FDA approves the indication of von Willebrand disease for Alphanate (Spanish Version)